Oncolys BioPharma
4588.TTSE GROWTHPharmaceutical
Financials · Standalone
| Fiscal year ended | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|---|
| Revenue | ¥29m | ¥31m | ¥63m | ¥976m | ¥642m | ¥314m |
| Operating income | −¥2.0bn | −¥1.7bn | −¥1.9bn | −¥1.2bn | −¥1.5bn | −¥1.7bn |
| Ordinary income | −¥2.1bn | −¥1.7bn | −¥1.9bn | −¥1.2bn | −¥1.5bn | −¥1.7bn |
| Total assets | ¥4.6bn | ¥3.2bn | ¥2.0bn | ¥2.7bn | ¥4.3bn | ¥2.8bn |
| Net assets / equity | ¥4.0bn | ¥2.8bn | ¥1.5bn | ¥2.2bn | ¥3.6bn | ¥2.0bn |
| Operating cash flow | −¥1.9bn | −¥2.0bn | −¥1.3bn | −¥1.7bn | −¥1.7bn | −¥1.5bn |
| EPS (basic) | ¥-80 | ¥-77.17 | ¥-108.92 | ¥-66.31 | ¥-95.5 | ¥-145.58 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 6
| Period | Form | Figures |
|---|---|---|
| 2024-01-01 → 2024-03-31 | Quarterly Q1 | 40 figures · EDINET |
| 2023-01-01 → 2023-09-30 | Quarterly Q3 | 44 figures · EDINET |
| 2023-01-01 → 2023-06-30 | Quarterly Q2 | 68 figures · EDINET |
| 2023-01-01 → 2023-03-31 | Quarterly Q1 | 42 figures · EDINET |
| 2022-01-01 → 2022-09-30 | Quarterly Q3 | 44 figures · EDINET |
| 2022-01-01 → 2022-06-30 | Quarterly Q2 | 68 figures · EDINET |
29 more reports are still being processed.